Ondine Biomedical Inc (AIM:OBI) has received the Tayyaba Hasan Impact Award at the 18th International Photodynamic Association (IPA) World Congress, which took place in Finland.
The award recognised Ondine for “demonstrating exceptional perseverance and clinical acumen".
"Ondine has demonstrated successful outcomes in a number of key studies for both prevention and treatment against strains of SARS-CoV-2 including deployment in large-scale enterprises,” the company noted in a statement.
The IPA promotes the benefits of light-activated therapies to treat infections that pose the biggest threats to global health security, it added.
Additionally, Ondine's senior scientist and lab manager Cristina Romo was honoured as an Early Investigator's award recipient.
"The international Congress recognises leaders from around the world, in their respective fields, for their contributions that continue to advance the field of photomedicine,” said Colin Hopper, president of the IPA board of directors.
“This team award recognises the collective efforts and successes in advancing the clinical safety and efficacy of photodynamic therapy for antiviral applications during the COVID-19 pandemic.
“The outcomes of this work and these studies will help to serve future pandemic preparedness and support the ongoing efforts for advanced antimicrobial resistance stewardship. Antimicrobial resistance is one of the top human health issues globally."